Recent studies proposing oral L‐serine therapy for HSAN49, 50 have highlighted its potential applicability for patients with early‐onset ALS carrying SPTLC1 or SPTLC2 variants. This evidence concerns the gene SPTLC1 and amyotrophic lateral sclerosis.